-
1
-
-
38749087581
-
Protective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity
-
Ahuja M., Bishnoi M., Chopra K. Protective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity. Toxicology 2008, 244(2-3):111-122.
-
(2008)
Toxicology
, vol.244
, Issue.2-3
, pp. 111-122
-
-
Ahuja, M.1
Bishnoi, M.2
Chopra, K.3
-
2
-
-
79952487439
-
Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial
-
Akhondzadeh S., Ghayyoumi R., Rezaei F., Salehi B., Modabbernia A.H., Maroufi A., Esfandiari G.R., Naderi M., Ghebleh F., Tabrizi M., Rezazadeh S.A. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology 2011, 213(4):809-815.
-
(2011)
Psychopharmacology
, vol.213
, Issue.4
, pp. 809-815
-
-
Akhondzadeh, S.1
Ghayyoumi, R.2
Rezaei, F.3
Salehi, B.4
Modabbernia, A.H.5
Maroufi, A.6
Esfandiari, G.R.7
Naderi, M.8
Ghebleh, F.9
Tabrizi, M.10
Rezazadeh, S.A.11
-
3
-
-
0003472502
-
-
American Psychiatric Association, Arlington, VA
-
American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Association, Arlington, VA. fifth ed.
-
(2013)
Diagnostic and Statistical Manual of Mental Disorders
-
-
-
4
-
-
23944476085
-
The many faces of nitric oxide in schizophrenia. A review
-
Bernstein H.G., Bogert B., Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophr. Res. 2005, 78(1):69-86.
-
(2005)
Schizophr. Res.
, vol.78
, Issue.1
, pp. 69-86
-
-
Bernstein, H.G.1
Bogert, B.2
Keilhoff, G.3
-
5
-
-
81155131944
-
Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy
-
Bernstein H.G., Keilhoff G., Steiner J., Dobrowolny H., Bogerts B. Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy. CNS Neurol. Disord. Drug Targets 2011, 10(7):792-807.
-
(2011)
CNS Neurol. Disord. Drug Targets
, vol.10
, Issue.7
, pp. 792-807
-
-
Bernstein, H.G.1
Keilhoff, G.2
Steiner, J.3
Dobrowolny, H.4
Bogerts, B.5
-
6
-
-
33846887598
-
Microglial control of neuronal death and synaptic properties
-
Bessis A., Béchade C., Bernard D., Roumier A. Microglial control of neuronal death and synaptic properties. Glia 2007, 55(3):233-238.
-
(2007)
Glia
, vol.55
, Issue.3
, pp. 233-238
-
-
Bessis, A.1
Béchade, C.2
Bernard, D.3
Roumier, A.4
-
7
-
-
0024378999
-
Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum
-
Bredt D.S., Snyder S.H. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc. Natl. Acad. Sci. U. S. A. 1989, 86(22):9030-9033.
-
(1989)
Proc. Natl. Acad. Sci. U. S. A.
, vol.86
, Issue.22
, pp. 9030-9033
-
-
Bredt, D.S.1
Snyder, S.H.2
-
8
-
-
84864999825
-
Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
-
Chaudhry I.B., Hallak J., Husain N., Minhas F., Stirling J., Richardson P., Dursun S., Dunn G., Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012, 26(9):1185-1193.
-
(2012)
J. Psychopharmacol.
, vol.26
, Issue.9
, pp. 1185-1193
-
-
Chaudhry, I.B.1
Hallak, J.2
Husain, N.3
Minhas, F.4
Stirling, J.5
Richardson, P.6
Dursun, S.7
Dunn, G.8
Deakin, B.9
-
9
-
-
0033600913
-
PSD-95 assembles a ternary complex with the N-methyl-d-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain
-
Christopherson K.S., Hillier B.J., Lim W.A., Bredt D.S. PSD-95 assembles a ternary complex with the N-methyl-d-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J. Biol. Chem. 1999, 274(39):27467-27473.
-
(1999)
J. Biol. Chem.
, vol.274
, Issue.39
, pp. 27467-27473
-
-
Christopherson, K.S.1
Hillier, B.J.2
Lim, W.A.3
Bredt, D.S.4
-
10
-
-
84880552098
-
Nitric oxide and symptom reduction in schizophrenia
-
Coyle J.T. Nitric oxide and symptom reduction in schizophrenia. JAMA Psychiatry 2013, 70(7):664-665.
-
(2013)
JAMA Psychiatry
, vol.70
, Issue.7
, pp. 664-665
-
-
Coyle, J.T.1
-
11
-
-
84859971485
-
Minocycline: therapeutic potential in psychiatry
-
Dean O.M., Data-Franco J., Giorlando F., Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs 2012, 26(5):391-401.
-
(2012)
CNS Drugs
, vol.26
, Issue.5
, pp. 391-401
-
-
Dean, O.M.1
Data-Franco, J.2
Giorlando, F.3
Berk, M.4
-
13
-
-
84929278460
-
Genome-wide gene pathway analysis of psychotic illness symptom dimensions based on a new schizophrenia-specific model of the OPCRIT
-
Docherty A.R., Bigdeli T.B., Edwards A.C., Bacanu S., Lee D., Neale M.C., Wormley B.K., Walsh D., O'Neill F.A., Riley B.P., Kendler K.S., Fanous A.H. Genome-wide gene pathway analysis of psychotic illness symptom dimensions based on a new schizophrenia-specific model of the OPCRIT. Schizophr. Res. 2015, 164(1-3):181-186.
-
(2015)
Schizophr. Res.
, vol.164
, Issue.1-3
, pp. 181-186
-
-
Docherty, A.R.1
Bigdeli, T.B.2
Edwards, A.C.3
Bacanu, S.4
Lee, D.5
Neale, M.C.6
Wormley, B.K.7
Walsh, D.8
O'Neill, F.A.9
Riley, B.P.10
Kendler, K.S.11
Fanous, A.H.12
-
14
-
-
84910026155
-
Antipsychotic-like effect of minocycline in a rat model
-
Dokuyucu R., Kokacya H., Inanir S., Copoglu U.S., Erbas O. Antipsychotic-like effect of minocycline in a rat model. Int. J. Clin. Exp. Med. 2014, 7(10):3354-3361.
-
(2014)
Int. J. Clin. Exp. Med.
, vol.7
, Issue.10
, pp. 3354-3361
-
-
Dokuyucu, R.1
Kokacya, H.2
Inanir, S.3
Copoglu, U.S.4
Erbas, O.5
-
15
-
-
84910026155
-
Antipsychotic-like effect of minocycline in a rat model
-
Dokuyucu R., Kokacya H., Inanir S., Copoglu U.S., Erbas O. Antipsychotic-like effect of minocycline in a rat model. Int. J. Clin. Exp. Med. 2014, 7(10):3354-3361.
-
(2014)
Int. J. Clin. Exp. Med.
, vol.7
, Issue.10
, pp. 3354-3361
-
-
Dokuyucu, R.1
Kokacya, H.2
Inanir, S.3
Copoglu, U.S.4
Erbas, O.5
-
16
-
-
0002556294
-
Abnormal mental states induced by phencyclidine as a model of schizophrenia
-
NPP Books, Ann Arbor, MI, E.F. Domino (Ed.)
-
Domino E.F., Luby E. Abnormal mental states induced by phencyclidine as a model of schizophrenia. Abnormal Mental States Induced by Phencyclidine as a Model of Schizophrenia 1981, 537. NPP Books, Ann Arbor, MI. E.F. Domino (Ed.).
-
(1981)
Abnormal Mental States Induced by Phencyclidine as a Model of Schizophrenia
, pp. 537
-
-
Domino, E.F.1
Luby, E.2
-
17
-
-
0026034352
-
NMDA receptor activation in rat hippocampus induces cyclic GMP formation through the l-arginine-nitric oxide pathway
-
East S.J., Garthwaite J. NMDA receptor activation in rat hippocampus induces cyclic GMP formation through the l-arginine-nitric oxide pathway. Neurosci. Lett. 1991, 123(1):17-19.
-
(1991)
Neurosci. Lett.
, vol.123
, Issue.1
, pp. 17-19
-
-
East, S.J.1
Garthwaite, J.2
-
18
-
-
0017046959
-
Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment
-
Ebstein R.P., Biederman J., Rimon R., Zohar J., Belmaker R.H. Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment. Psychopharmacology 1976, 51(1):71-74.
-
(1976)
Psychopharmacology
, vol.51
, Issue.1
, pp. 71-74
-
-
Ebstein, R.P.1
Biederman, J.2
Rimon, R.3
Zohar, J.4
Belmaker, R.H.5
-
19
-
-
27744494899
-
Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction
-
Francis S.H., Corbin J.D. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. Urol. Clin. North Am. 2005, 32(4):419-429.
-
(2005)
Urol. Clin. North Am.
, vol.32
, Issue.4
, pp. 419-429
-
-
Francis, S.H.1
Corbin, J.D.2
-
20
-
-
21344459311
-
Molecular properties of mammalian proteins that interact with cGMP: proteinkinases, cation channels, phosphodiesterases, and multi-drug anion transporters
-
(2005)
-
Francis S.H., Blount M.A., Zoraghi R., Corbin J.D. Molecular properties of mammalian proteins that interact with cGMP: proteinkinases, cation channels, phosphodiesterases, and multi-drug anion transporters. Front. Biosci. 2005, 10:2097-2117. (2005).
-
(2005)
Front. Biosci.
, vol.10
, pp. 2097-2117
-
-
Francis, S.H.1
Blount, M.A.2
Zoraghi, R.3
Corbin, J.D.4
-
21
-
-
77956283047
-
CGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action
-
Francis S.H., Busch J.L., Corbin J.D., Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol. Rev. 2010, 62(3):525-563.
-
(2010)
Pharmacol. Rev.
, vol.62
, Issue.3
, pp. 525-563
-
-
Francis, S.H.1
Busch, J.L.2
Corbin, J.D.3
Sibley, D.4
-
22
-
-
38749139293
-
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline
-
Fujita Y., Ishima T., Kunitachi S., Hagiwara H., Zhang L., Iyo M., Hashimoto K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol. Psychiatry 2007, 32(2):336-339.
-
(2007)
Prog Neuropsychopharmacol Biol. Psychiatry
, vol.32
, Issue.2
, pp. 336-339
-
-
Fujita, Y.1
Ishima, T.2
Kunitachi, S.3
Hagiwara, H.4
Zhang, L.5
Iyo, M.6
Hashimoto, K.7
-
23
-
-
84870927178
-
What is behind the non-antibiotic properties of minocycline?
-
Garrido-Mesa N., Zarzuelo A., Gálvez J. What is behind the non-antibiotic properties of minocycline?. Pharmacol. Res. 2013, 67(1):18-30.
-
(2013)
Pharmacol. Res.
, vol.67
, Issue.1
, pp. 18-30
-
-
Garrido-Mesa, N.1
Zarzuelo, A.2
Gálvez, J.3
-
24
-
-
0024462440
-
NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices
-
Garthwaite J., Garthwaite G., Palmer R.M., Moncada S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur. J. Pharmacol. 1989, 172(4-5):413-416.
-
(1989)
Eur. J. Pharmacol.
, vol.172
, Issue.4-5
, pp. 413-416
-
-
Garthwaite, J.1
Garthwaite, G.2
Palmer, R.M.3
Moncada, S.4
-
25
-
-
0020574890
-
Low CSF concentrations of cyclic GMP in schizophrenia
-
Gattaz W.F., Cramer H., Beckmann H. Low CSF concentrations of cyclic GMP in schizophrenia. Br. J. Psychiatry 1983, 142:288-291.
-
(1983)
Br. J. Psychiatry
, vol.142
, pp. 288-291
-
-
Gattaz, W.F.1
Cramer, H.2
Beckmann, H.3
-
26
-
-
84920609519
-
Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial
-
Ghanizadeh A., Dehbozorgi S., Sigaroodi M.O., Rezaei Z. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent Patents Inflamm. Allergy Drug Discov. 2014, 8(3):211-215.
-
(2014)
Recent Patents Inflamm. Allergy Drug Discov.
, vol.8
, Issue.3
, pp. 211-215
-
-
Ghanizadeh, A.1
Dehbozorgi, S.2
Sigaroodi, M.O.3
Rezaei, Z.4
-
27
-
-
59449098930
-
A placebo-controlled study of sildenafil effects on cognition in schizophrenia
-
Goff D.C., Cather C., Freudenreich O., Henderson D.C., Evins A.E., Culhane M.A., Walsh J.P. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology 2009, 202(1-3):411-417.
-
(2009)
Psychopharmacology
, vol.202
, Issue.1-3
, pp. 411-417
-
-
Goff, D.C.1
Cather, C.2
Freudenreich, O.3
Henderson, D.C.4
Evins, A.E.5
Culhane, M.A.6
Walsh, J.P.7
-
28
-
-
35148895860
-
PDE inhibitors in psychiatry-future options for dementia, depression and schizophrenia?
-
Halene T.B., Siegel S.J. PDE inhibitors in psychiatry-future options for dementia, depression and schizophrenia?. Drug Discov. Today 2007, 12(19-20):870-878.
-
(2007)
Drug Discov. Today
, vol.12
, Issue.19-20
, pp. 870-878
-
-
Halene, T.B.1
Siegel, S.J.2
-
29
-
-
84880530466
-
Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial
-
Hallak J.E., Maia-de-Oliveira J.P., Abrao J., Evora P.R., Zuardi A.W., Crippa J.A., Belmonte-de-Abreu P., Baker G.B., Dursun S.M. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 2013, 70(7):668-676.
-
(2013)
JAMA Psychiatry
, vol.70
, Issue.7
, pp. 668-676
-
-
Hallak, J.E.1
Maia-de-Oliveira, J.P.2
Abrao, J.3
Evora, P.R.4
Zuardi, A.W.5
Crippa, J.A.6
Belmonte-de-Abreu, P.7
Baker, G.B.8
Dursun, S.M.9
-
30
-
-
33847276567
-
Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys
-
Hashimoto K., Tsukada H., Nishiyama S., Fukumoto D., Kakiuchi T., Iyo M. Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys. Biol. Psychiatry 2007, 61(5):577-581.
-
(2007)
Biol. Psychiatry
, vol.61
, Issue.5
, pp. 577-581
-
-
Hashimoto, K.1
Tsukada, H.2
Nishiyama, S.3
Fukumoto, D.4
Kakiuchi, T.5
Iyo, M.6
-
31
-
-
0026779303
-
Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats
-
Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm. Gen. Sect. 1992, 89(1-2):1-10.
-
(1992)
J. Neural Transm. Gen. Sect.
, vol.89
, Issue.1-2
, pp. 1-10
-
-
Hoffman, D.C.1
-
32
-
-
84883188866
-
CGMP-dependent protein kinases (cGK)
-
Hofmann F., Wegener J.W. cGMP-dependent protein kinases (cGK). Methods Mol. Biol. 2013, 1020:17-50.
-
(2013)
Methods Mol. Biol.
, vol.1020
, pp. 17-50
-
-
Hofmann, F.1
Wegener, J.W.2
-
33
-
-
79959999316
-
The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents
-
Hutson P.H., Finger E.N., Magliaro B.C., Smith S.M., Converso A., Sanderson P.E., Mullins D., Hyde L.A., Eschle B.K., Turnbull Z., Sloan H., Guzzi M., Zhang X., Wang A., Rindgen D., Mazzola R., Vivian J.A., Eddins D., Uslaner J.M., Bednar R., Gambone C., Le-Mair W., Marino M.J., Sachs N., Xu G., Parmentier-Batteur S. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 2011, 61(4):665-676.
-
(2011)
Neuropharmacology
, vol.61
, Issue.4
, pp. 665-676
-
-
Hutson, P.H.1
Finger, E.N.2
Magliaro, B.C.3
Smith, S.M.4
Converso, A.5
Sanderson, P.E.6
Mullins, D.7
Hyde, L.A.8
Eschle, B.K.9
Turnbull, Z.10
Sloan, H.11
Guzzi, M.12
Zhang, X.13
Wang, A.14
Rindgen, D.15
Mazzola, R.16
Vivian, J.A.17
Eddins, D.18
Uslaner, J.M.19
Bednar, R.20
Gambone, C.21
Le-Mair, W.22
Marino, M.J.23
Sachs, N.24
Xu, G.25
Parmentier-Batteur, S.26
more..
-
34
-
-
0032707717
-
Nitric oxide as a signaling molecule in the vascular system: an overview
-
Ignarro L.J., Cirino G., Casini A., Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J. Cardiovasc. Pharmacol. 1999, 34(6):879-886.
-
(1999)
J. Cardiovasc. Pharmacol.
, vol.34
, Issue.6
, pp. 879-886
-
-
Ignarro, L.J.1
Cirino, G.2
Casini, A.3
Napoli, C.4
-
35
-
-
84893957793
-
Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice
-
Issy A.C., Pedrazzi J.F., Yoneyama B.H., Del-Bel E.A. Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice. Psychopharmacology 2014, 231(4):663-672.
-
(2014)
Psychopharmacology
, vol.231
, Issue.4
, pp. 663-672
-
-
Issy, A.C.1
Pedrazzi, J.F.2
Yoneyama, B.H.3
Del-Bel, E.A.4
-
37
-
-
79953296930
-
PDE10A inhibitors: novel therapeutic drugs for schizophrenia
-
Kehler J., Nielsen J. PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr. Pharm. Des. 2011, 17(2):137-150.
-
(2011)
Curr. Pharm. Des.
, vol.17
, Issue.2
, pp. 137-150
-
-
Kehler, J.1
Nielsen, J.2
-
38
-
-
84895073675
-
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
-
Kennedy J.L., Altar C.A., Taylor D.L., Degtiar I., Hornberger J.C. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int. Clin. Psychopharmacol. 2014, 29(2):63-76.
-
(2014)
Int. Clin. Psychopharmacol.
, vol.29
, Issue.2
, pp. 63-76
-
-
Kennedy, J.L.1
Altar, C.A.2
Taylor, D.L.3
Degtiar, I.4
Hornberger, J.C.5
-
39
-
-
84900095329
-
Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study
-
Khodaie-Ardakani M.R., Mirshafiee O., Farokhnia M., Tajdini M., Hosseini S.M., Modabbernia A., Rezaei F., Salehi B., Yekehtaz H., Ashrafi M., Tabrizi M., Akhondzadeh S. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res. 2014, 215(3):540-546.
-
(2014)
Psychiatry Res.
, vol.215
, Issue.3
, pp. 540-546
-
-
Khodaie-Ardakani, M.R.1
Mirshafiee, O.2
Farokhnia, M.3
Tajdini, M.4
Hosseini, S.M.5
Modabbernia, A.6
Rezaei, F.7
Salehi, B.8
Yekehtaz, H.9
Ashrafi, M.10
Tabrizi, M.11
Akhondzadeh, S.12
-
40
-
-
7044286205
-
Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells
-
Kim S.S., Kong P.J., Kim B.S., Sheen D.H., Nam S.Y., Chun W. Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch. Pharm. Res. 2004, 27(3):314-318.
-
(2004)
Arch. Pharm. Res.
, vol.27
, Issue.3
, pp. 314-318
-
-
Kim, S.S.1
Kong, P.J.2
Kim, B.S.3
Sheen, D.H.4
Nam, S.Y.5
Chun, W.6
-
41
-
-
84961931877
-
Comparison of PDE9 and PDE10 inhibitors in preclinical schizophrenia models
-
(Online. Available at
-
Kleiman R.J. Comparison of PDE9 and PDE10 inhibitors in preclinical schizophrenia models. Presented at the New York Academy of Sciences, New York, NY 2010, (Online. Available at http://www.nyas.org/Publications/Media/VideoDetail.aspx?cid=2cce36ba-5fd6-4de1-b84e-8b018624bf17).
-
(2010)
Presented at the New York Academy of Sciences, New York, NY
-
-
Kleiman, R.J.1
-
42
-
-
84859991527
-
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo
-
Kleiman R.J., Chapin D.S., Christoffersen C., Freeman J., Fonseca K.R., Geoghegan K.F., Grimwood S., Guanowsky V., Hajós M., Harms J.F., Helal C.J., Hoffmann W.E., Kocan G.P., Majchrzak M.J., McGinnis D., McLean S., Menniti F.S., Nelson F., Roof R., Schmidt A.W., Seymour P.A., Stephenson D.T., Tingley F.D., Vanase-Frawley M., Verhoest P.R., Schmidt C.J. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J. Pharmacol. Exp. Ther. 2012, 341(2):396-409.
-
(2012)
J. Pharmacol. Exp. Ther.
, vol.341
, Issue.2
, pp. 396-409
-
-
Kleiman, R.J.1
Chapin, D.S.2
Christoffersen, C.3
Freeman, J.4
Fonseca, K.R.5
Geoghegan, K.F.6
Grimwood, S.7
Guanowsky, V.8
Hajós, M.9
Harms, J.F.10
Helal, C.J.11
Hoffmann, W.E.12
Kocan, G.P.13
Majchrzak, M.J.14
McGinnis, D.15
McLean, S.16
Menniti, F.S.17
Nelson, F.18
Roof, R.19
Schmidt, A.W.20
Seymour, P.A.21
Stephenson, D.T.22
Tingley, F.D.23
Vanase-Frawley, M.24
Verhoest, P.R.25
Schmidt, C.J.26
more..
-
43
-
-
0028323167
-
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
-
Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51(3):199-214.
-
(1994)
Arch. Gen. Psychiatry
, vol.51
, Issue.3
, pp. 199-214
-
-
Krystal, J.H.1
Karper, L.P.2
Seibyl, J.P.3
Freeman, G.K.4
Delaney, R.5
Bremner, J.D.6
Heninger, G.R.7
Bowers, M.B.8
Charney, D.S.9
-
44
-
-
34249804458
-
Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia
-
Levkovitz Y., Levi U., Braw Y., Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007, 1154:154-162.
-
(2007)
Brain Res.
, vol.1154
, pp. 154-162
-
-
Levkovitz, Y.1
Levi, U.2
Braw, Y.3
Cohen, H.4
-
45
-
-
77649112679
-
A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
-
Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., Fennig S., Treves I., Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 2010, 71(2):138-149.
-
(2010)
J. Clin. Psychiatry
, vol.71
, Issue.2
, pp. 138-149
-
-
Levkovitz, Y.1
Mendlovich, S.2
Riwkes, S.3
Braw, Y.4
Levkovitch-Verbin, H.5
Gal, G.6
Fennig, S.7
Treves, I.8
Kron, S.9
-
46
-
-
84895818899
-
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial
-
Liu F., Guo X., Wu R., Ou J., Zheng Y., Zhang B., Xie L., Zhang L., Yang L., Yang S., Yang J., Ruan Y., Zeng Y., Xu X., Zhao J. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr. Res. 2014, 153(1-3):169-176.
-
(2014)
Schizophr. Res.
, vol.153
, Issue.1-3
, pp. 169-176
-
-
Liu, F.1
Guo, X.2
Wu, R.3
Ou, J.4
Zheng, Y.5
Zhang, B.6
Xie, L.7
Zhang, L.8
Yang, L.9
Yang, S.10
Yang, J.11
Ruan, Y.12
Zeng, Y.13
Xu, X.14
Zhao, J.15
-
47
-
-
57049135076
-
In vivo effects of phosphodiesterase inhibition on basal cyclic guanosine monophosphate levels in the prefrontal cortex, hippocampus and cerebellum of freely moving rats
-
Marte A., Pepicelli O., Cavallero A., Raiteri M., Fedele E. In vivo effects of phosphodiesterase inhibition on basal cyclic guanosine monophosphate levels in the prefrontal cortex, hippocampus and cerebellum of freely moving rats. J. Neurosci. Res. 2008, 86(15):3338-3347.
-
(2008)
J. Neurosci. Res.
, vol.86
, Issue.15
, pp. 3338-3347
-
-
Marte, A.1
Pepicelli, O.2
Cavallero, A.3
Raiteri, M.4
Fedele, E.5
-
48
-
-
84897443197
-
Advances in targeting cyclic nucleotide phosphodiesterases
-
Maurice D.H., Ke H., Ahmad F., Wang Y., Chung J., Manganiello V.C. Advances in targeting cyclic nucleotide phosphodiesterases. Nat. Rev. Drug Discov. 2014, 13(4):290-314.
-
(2014)
Nat. Rev. Drug Discov.
, vol.13
, Issue.4
, pp. 290-314
-
-
Maurice, D.H.1
Ke, H.2
Ahmad, F.3
Wang, Y.4
Chung, J.5
Manganiello, V.C.6
-
49
-
-
12344326514
-
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
-
Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10:79-104.
-
(2005)
Mol. Psychiatry
, vol.10
, pp. 79-104
-
-
Miyamoto, S.1
Duncan, G.E.2
Marx, C.E.3
Lieberman, J.A.4
-
50
-
-
84908619928
-
Microglial intracellular Ca(2+) signaling as a target of antipsychotic actions for the treatment of schizophrenia
-
Mizoguchi Y., Kato T.A., Horikawa H., Monji A. Microglial intracellular Ca(2+) signaling as a target of antipsychotic actions for the treatment of schizophrenia. Front. Cell. Neurosci. 2014, 8:370.
-
(2014)
Front. Cell. Neurosci.
, vol.8
, pp. 370
-
-
Mizoguchi, Y.1
Kato, T.A.2
Horikawa, H.3
Monji, A.4
-
51
-
-
0032575715
-
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
-
Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281(5381):1349-1352.
-
(1998)
Science
, vol.281
, Issue.5381
, pp. 1349-1352
-
-
Moghaddam, B.1
Adams, B.W.2
-
52
-
-
84885779392
-
Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathways
-
Monte A.S., de Souza G.C., McIntyre R.S., Soczynska J.K., dos Santos J.V., Cordeiro R.C., Ribeiro B.M., de Lucena D.F., Vasconcelos S.M., de Sousa F.C., Carvalho A.F., Macêdo D.S. Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathways. J. Psychopharmacol. 2013, 27(11):1032-1043.
-
(2013)
J. Psychopharmacol.
, vol.27
, Issue.11
, pp. 1032-1043
-
-
Monte, A.S.1
de Souza, G.C.2
McIntyre, R.S.3
Soczynska, J.K.4
dos Santos, J.V.5
Cordeiro, R.C.6
Ribeiro, B.M.7
de Lucena, D.F.8
Vasconcelos, S.M.9
de Sousa, F.C.10
Carvalho, A.F.11
Macêdo, D.S.12
-
53
-
-
33847068206
-
Overview of PDEs and their regulation
-
Omori K., Kotera J. Overview of PDEs and their regulation. Circ. Res. 2007, 100(3):309-327.
-
(2007)
Circ. Res.
, vol.100
, Issue.3
, pp. 309-327
-
-
Omori, K.1
Kotera, J.2
-
54
-
-
84902595080
-
Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia
-
Qurashi I., Collins J., Chaudhry I., Husain N. Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. J. Psychopharmacol. 2014, 28(7):707-708.
-
(2014)
J. Psychopharmacol.
, vol.28
, Issue.7
, pp. 707-708
-
-
Qurashi, I.1
Collins, J.2
Chaudhry, I.3
Husain, N.4
-
55
-
-
1842790618
-
Bidirectional regulation of neuronal nitric-oxide synthase phosphorylation at serine 847 by the N-methyl-d-aspartate receptor
-
Rameau G.A., Chiu L.Y., Ziff E.B. Bidirectional regulation of neuronal nitric-oxide synthase phosphorylation at serine 847 by the N-methyl-d-aspartate receptor. J. Biol. Chem. 2004, 279(14):14307-14314.
-
(2004)
J. Biol. Chem.
, vol.279
, Issue.14
, pp. 14307-14314
-
-
Rameau, G.A.1
Chiu, L.Y.2
Ziff, E.B.3
-
56
-
-
84872294654
-
The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans
-
Reneerkens O.A., Sambeth A., Van Duinen M.A., Blokland A., Steinbusch H.W., Prickaerts J. The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans. Psychopharmacology 2013, 225(2):303-312.
-
(2013)
Psychopharmacology
, vol.225
, Issue.2
, pp. 303-312
-
-
Reneerkens, O.A.1
Sambeth, A.2
Van Duinen, M.A.3
Blokland, A.4
Steinbusch, H.W.5
Prickaerts, J.6
-
57
-
-
0032190029
-
Functional properties of a naturally occurring isoform of soluble guanylyl cyclase
-
Russwurm M., Behrends S., Harteneck C., Koesling D. Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. Biochem. J. 1998, 335(Pt 1):125-130.
-
(1998)
Biochem. J.
, vol.335
, pp. 125-130
-
-
Russwurm, M.1
Behrends, S.2
Harteneck, C.3
Koesling, D.4
-
58
-
-
84883185689
-
NO/cGMP: the past, the present, and the future
-
Russwurm M., Russwurm C., Koesling D., Mergia E. NO/cGMP: the past, the present, and the future. Methods Mol. Biol. 2013, 1020:1-16.
-
(2013)
Methods Mol. Biol.
, vol.1020
, pp. 1-16
-
-
Russwurm, M.1
Russwurm, C.2
Koesling, D.3
Mergia, E.4
-
59
-
-
0030844332
-
Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test
-
Sams-Dodd F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav. Pharmacol. 1997, 8(2-3):196-215.
-
(1997)
Behav. Pharmacol.
, vol.8
, Issue.2-3
, pp. 196-215
-
-
Sams-Dodd, F.1
-
60
-
-
0033599714
-
Schizophrenia
-
Schultz S.K., Andreasen N.C. Schizophrenia. Lancet 1999, 353(9162):1425-1430.
-
(1999)
Lancet
, vol.353
, Issue.9162
, pp. 1425-1430
-
-
Schultz, S.K.1
Andreasen, N.C.2
-
61
-
-
38849147799
-
Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site
-
Shim S.S., Hammonds M.D., Kee B.S. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur. Arch. Psychiatry Clin. Neurosci. 2007, 258(1):16-27.
-
(2007)
Eur. Arch. Psychiatry Clin. Neurosci.
, vol.258
, Issue.1
, pp. 16-27
-
-
Shim, S.S.1
Hammonds, M.D.2
Kee, B.S.3
-
62
-
-
55949132109
-
The role of phosphodiesterases in schizophrenia: therapeutic implications
-
Siuciak J.A. The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 2008, 22(12):983-993.
-
(2008)
CNS Drugs
, vol.22
, Issue.12
, pp. 983-993
-
-
Siuciak, J.A.1
-
63
-
-
0030057542
-
The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis
-
Steinpreis R.E. The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav. Brain Res. 1996, 74(1-2):45-55.
-
(1996)
Behav. Brain Res.
, vol.74
, Issue.1-2
, pp. 45-55
-
-
Steinpreis, R.E.1
-
64
-
-
5844284193
-
Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide
-
Stone J.R., Marletta M.A. Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide. Biochemistry 1996, 35(4):1093-1099.
-
(1996)
Biochemistry
, vol.35
, Issue.4
, pp. 1093-1099
-
-
Stone, J.R.1
Marletta, M.A.2
-
65
-
-
79951678468
-
Neuroprotective mechanisms of minocycline against sphingomyelinase/ceramide toxicity: roles of Bcl-2 and thioredoxin
-
Tang C.M., Hwang C.S., Chen S.D., Yang D.I. Neuroprotective mechanisms of minocycline against sphingomyelinase/ceramide toxicity: roles of Bcl-2 and thioredoxin. Free Radic. Biol. Med. 2011, 50(6):710-721.
-
(2011)
Free Radic. Biol. Med.
, vol.50
, Issue.6
, pp. 710-721
-
-
Tang, C.M.1
Hwang, C.S.2
Chen, S.D.3
Yang, D.I.4
-
66
-
-
1442326012
-
Minocycline: neuroprotective mechanisms in Parkinson's disease
-
Thomas M., Le W.D. Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr. Pharm. Des. 2004, 10(6):679-686.
-
(2004)
Curr. Pharm. Des.
, vol.10
, Issue.6
, pp. 679-686
-
-
Thomas, M.1
Le, W.D.2
-
67
-
-
77949447469
-
Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis
-
Tsai G.E., Lin P. Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 2010, 16(5):522-537.
-
(2010)
Curr. Pharm. Des.
, vol.16
, Issue.5
, pp. 522-537
-
-
Tsai, G.E.1
Lin, P.2
-
69
-
-
84883551131
-
Free radicals, antioxidant defense systems, and schizophrenia
-
Wu J.Q., Kosten T.R., Zhang X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 46:200-206.
-
(2013)
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
, vol.46
, pp. 200-206
-
-
Wu, J.Q.1
Kosten, T.R.2
Zhang, X.Y.3
-
70
-
-
27844464469
-
Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line
-
Wunder F., Tersteegen A., Rebmann A., Erb C., Fahrig T., Hendrix M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol. Pharmacol. 2005, 68(6):1775-1781.
-
(2005)
Mol. Pharmacol.
, vol.68
, Issue.6
, pp. 1775-1781
-
-
Wunder, F.1
Tersteegen, A.2
Rebmann, A.3
Erb, C.4
Fahrig, T.5
Hendrix, M.6
-
71
-
-
8844254741
-
The promise of minocycline in neurology
-
Yong V.W., Wells J., Giuliani F., Casha S., Power C., Metz L.M. The promise of minocycline in neurology. Lancet Neurol. 2004, 3(12):744-751.
-
(2004)
Lancet Neurol.
, vol.3
, Issue.12
, pp. 744-751
-
-
Yong, V.W.1
Wells, J.2
Giuliani, F.3
Casha, S.4
Power, C.5
Metz, L.M.6
-
72
-
-
84902578330
-
Profile of minocycline and its potential in the treatment of schizophrenia
-
Zhang L., Zhao J. Profile of minocycline and its potential in the treatment of schizophrenia. Neuropsychiatr. Dis. Treat. 2014, 10:1103-1111.
-
(2014)
Neuropsychiatr. Dis. Treat.
, vol.10
, pp. 1103-1111
-
-
Zhang, L.1
Zhao, J.2
-
73
-
-
33750338069
-
Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine
-
Zhang L., Kitaichi K., Fujimoto Y., Nakayama H., Shimizu E., Iyo M., Hashimoto K. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2006, 30(8):1381-1393.
-
(2006)
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
, vol.30
, Issue.8
, pp. 1381-1393
-
-
Zhang, L.1
Kitaichi, K.2
Fujimoto, Y.3
Nakayama, H.4
Shimizu, E.5
Iyo, M.6
Hashimoto, K.7
-
74
-
-
34547884686
-
Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine
-
Zhang L., Shirayama Y., Iyo M., Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007, 32(9):2004-2010.
-
(2007)
Neuropsychopharmacology
, vol.32
, Issue.9
, pp. 2004-2010
-
-
Zhang, L.1
Shirayama, Y.2
Iyo, M.3
Hashimoto, K.4
-
75
-
-
84898873540
-
Minocycline alleviates behavioral deficits and inhibits microglial activation induced by intrahippocampal administration of granulocyte-macrophage colony-stimulating factor in adult rats
-
Zhu F., Liu Y., Zhao J., Zheng Y. Minocycline alleviates behavioral deficits and inhibits microglial activation induced by intrahippocampal administration of granulocyte-macrophage colony-stimulating factor in adult rats. Neurobiologia 2014, 266:275-281.
-
(2014)
Neurobiologia
, vol.266
, pp. 275-281
-
-
Zhu, F.1
Liu, Y.2
Zhao, J.3
Zheng, Y.4
-
76
-
-
84899109433
-
Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats
-
Zhu F., Zheng Y., Ding Y.Q., Liu Y., Zhang X., Wu R., Guo X., Zhao J. Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats. PLoS One 2014, 9(4):e93966.
-
(2014)
PLoS One
, vol.9
, Issue.4
-
-
Zhu, F.1
Zheng, Y.2
Ding, Y.Q.3
Liu, Y.4
Zhang, X.5
Wu, R.6
Guo, X.7
Zhao, J.8
|